SCOPE: Observational Study of the Consequences of the Protease Inhibitor Era

Study acronym: SCOPE
StatusRecruiting
PhaseNot specified
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. 3 versions Re-verified since Jun 17, 2024, no change to tracked fieldsv24-v26
  2. Primary completion date: Dec 2022 to Dec 2032
    • Study completion date: Dec 2023 to Dec 2033
    v23
  3. 3 versions Re-verified since Feb 7, 2020, no change to tracked fieldsv20-v22
  4. Primary completion date: Mar 2019 to Dec 2022
    • Study completion date: Dec 2020 to Dec 2023
    v19
  5. Re-verified, no change to tracked fieldsv18
Show 16 earlier versionsHide 16 earlier versions
  1. Primary completion date: Mar 2015 to Mar 2019
    • Enrollment target: 2000 to 2500
    • Study completion date: Dec 2018 to Dec 2020
    • Site contact updated
    v17
  2. 2 versions Re-verified since Jan 7, 2014, no change to tracked fieldsv15-v16
  3. Study Status, Outcome Measuresv14
  4. Primary completion date: Mar 2015
    • Study completion date: Dec 2014 to Dec 2018
    v13
  5. Eligibility criteria expanded, about 8 wordsv12
  6. Site contact updatedv11
  7. Re-verified, no change to tracked fieldsv10
  8. Study completion date: Dec 2014v9
  9. Eligibility criteria expanded, about 9 wordsv8
  10. Enrollment target: 500 to 2000
    • Eligibility criteria expanded, about 15 words
    v7
  11. 3 versions Re-verified since Sep 6, 2006, no change to tracked fieldsv4-v6
  12. Study description shortened, about 9 wordsv3
  13. Study description revised
    • Eligibility criteria shortened, about 4 words
    v2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
SCOPE is an observational, prospective study of HIV-1 infected volunteers designed to provide a specimen bank of samples with carefully characterized clinical data. SCOPE specimens will be used to examine multiple questions involving virologic, immunologic, and host factors involved in HIV-1 infection, progression, non-progression, response to treatment, control of HIV-1 virus, and evolution of drug resistance.
Trial Details
NCT Number NCT00187512
Lead Sponsor University of California, San Francisco
Collaborators: National Institute of Allergy and Infectious Diseases (NIAID)
Conditions
(from sponsor)		 HIV Infections
Related terms HIV Infections
Enrollment 2,500 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov